AGR2 Inhibitors

The chemical class of AGR2 inhibitors comprises a range of compounds that indirectly impact the expression or activity of AGR2 through modulation of cellular stress responses, signaling pathways, and metabolic processes. This class includes agents like phenethyl isothiocyanate (PEITC) and quercetin, which are known to induce endoplasmic reticulum (ER) stress. By overwhelming the protein folding capacity of the cell, these compounds might lead to a reduction in AGR2 expression, a protein involved in the ER-associated protein folding process. Compounds that alter key cellular signaling pathways, such as U0126, a MEK inhibitor, and LY294002, a PI3K inhibitor, also form a significant part of this class. By modulating pathways like ERK/MAPK and AKT/mTOR, these inhibitors can indirectly decrease AGR2 expression, reflecting the complex interplay between various cellular signaling mechanisms and the regulation of proteins involved in stress responses.

Additionally, metabolic inhibitors like 2-Deoxy-D-glucose and drugs affecting protein folding and degradation pathways, such as bortezomib and 17-AAG, underscore the diverse mechanisms through which AGR2 can be indirectly inhibited. These compounds, by inducing energy stress or inhibiting proteasome and Hsp90 functions, respectively, can lead to a decrease in AGR2 expression as part of the cellular adaptive response to these stressors. Furthermore, natural compounds like curcumin and resveratrol are included in this class due to their broad effects on cellular pathways. By modulating processes associated with protein folding, ER stress, and cellular aging, these compounds can potentially reduce AGR2 expression. The presence of rapamycin, an mTOR inhibitor, and chloroquine, affecting autophagy pathways, further illustrates the wide range of mechanisms through which these inhibitors can indirectly impact AGR2 activity.